VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
PRICE: 0 CENTS
Sunday, December 28, 2025
Corteva, Inc.
CTVA · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Corteva is a global agricultural inputs company with two core segments: Seed (commercial seeds and traits) and Crop Protection (herbicides, insecticides, fungicides, seed treatments, and biologicals). The Seed segment's moat is largely IP- and R&D-driven, with management emphasizing advanced genetics, out-licensing, and sustained R&D investment. Crop Protection benefits from differentiated technology and a steady stream of new products/biologicals, but pricing is often constrained by competitive dynamics and generics. Corteva has announced a plan to separate the Seed and Crop Protection businesses into two public companies in the second half of 2026, which could alter the integration benefits of system offerings.
Primary segment
Seed
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
2 segments · 7 tags
Updated 2025-12-28
Segments
Seed
Commercial agricultural seeds and traits (corn, soybean, and other crops)
Revenue
56.5%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Crop Protection
Crop protection (herbicides, insecticides, fungicides, seed treatments, and biologicals)
Revenue
43.5%
Structure
Oligopoly
Pricing
weak
Share
—
Peers
Moat Claims
Seed
Commercial agricultural seeds and traits (corn, soybean, and other crops)
Revenue share (56.5%) based on Corteva 2024 net sales mix cited by Reuters; segment is planned to be separated into a standalone seed company (2H 2026).
IP Choke Point
Legal
IP Choke Point
Strength: 4/5 · Durability: medium · Confidence: 4/5 · 2 evidence
Trait and germplasm IP can be monetized via out-licensing/royalties and helps defend differentiated seed performance.
Erosion risks
- Trait patent expirations and generic trait entry
- Regulatory restrictions on biotech traits or gene-editing
- Breakthrough competitor genetics/traits reduce differentiation
Leading indicators
- Out-licensing/royalty income trend
- Adoption rates of core trait platforms (e.g., Enlist system)
- Pipeline milestones and regulatory approvals for new traits
Counterarguments
- Large competitors also hold extensive trait IP; licensing can be reciprocal
- Farmers can switch seed brands annually if performance/price disappoints
Learning Curve Yield
Supply
Learning Curve Yield
Strength: 4/5 · Durability: medium · Confidence: 4/5 · 2 evidence
Scale R&D and breeding pipelines improve hybrid/variety performance and speed of commercialization across regions.
Erosion risks
- R&D productivity slowdown (lower yield gains per dollar)
- Faster competitor product cycles (e.g., AI-enabled breeding)
- Farmer down-cycling to lower-priced seed alternatives
Leading indicators
- R&D expense trend and pipeline launch cadence
- Relative performance in third-party yield trials
- Seed price/mix realization vs prior year
Counterarguments
- Modern breeding/genomics tools can reduce the advantage of scale
- Higher R&D spend does not guarantee superior hybrids/varieties
Suite Bundling
Demand
Suite Bundling
Strength: 3/5 · Durability: medium · Confidence: 3/5 · 2 evidence
Integrated 'system' offerings (seed traits + compatible crop protection programs) can increase adoption and reinforce customer preference in key crops.
Erosion risks
- Planned separation could reduce cross-segment bundling benefits
- Antitrust/regulatory scrutiny of bundling practices
- Competitors offer similar trait+chemistry systems
Leading indicators
- Adoption/penetration of system-based programs in major crops
- Cross-sell rates between seed and crop protection channels
- Customer retention in key geographies
Counterarguments
- Many farmers choose seed and chemistry separately; bundling may be limited
- A corporate separation can unwind integration benefits
Crop Protection
Crop protection (herbicides, insecticides, fungicides, seed treatments, and biologicals)
Revenue share (43.5%) based on Corteva 2024 net sales mix cited by Reuters; segment is planned to remain as 'New Corteva' post-separation (2H 2026).
IP Choke Point
Legal
IP Choke Point
Strength: 3/5 · Durability: medium · Confidence: 3/5 · 1 evidence
A steady stream of differentiated new products (including biologicals) supports share and margin where products are protected by patents, regulatory data, and know-how.
Erosion risks
- Patent expiry and generic competition
- Regulatory bans/restrictions on specific active ingredients
- Pest/weed resistance reduces product efficacy
Leading indicators
- Sales mix from newer products vs legacy portfolio
- Gross margin and price realization by region
- Regulatory outcomes and re-registration timelines
Counterarguments
- Crop protection markets often commoditize quickly as generics enter
- Competitors can match portfolios via acquisition or in-licensing
Operational Excellence
Supply
Operational Excellence
Strength: 3/5 · Durability: medium · Confidence: 3/5 · 1 evidence
Productivity programs and scale can support cost position and margin resilience versus smaller players, though peers also have large-scale operations.
Erosion risks
- Raw material inflation or supply shocks
- Manufacturing/quality disruptions
- Peers match cost position through their own productivity programs
Leading indicators
- Segment operating EBITDA margin trend
- Manufacturing utilization and cost-per-unit trend
- Inventory and working capital swings through the cycle
Counterarguments
- Cost advantages are hard to sustain against similarly scaled incumbents
- Regional price wars (e.g., Latin America) can overwhelm cost improvements
Suite Bundling
Demand
Suite Bundling
Strength: 3/5 · Durability: medium · Confidence: 3/5 · 2 evidence
Integrated crop programs with complementary seed traits can increase adoption of specific herbicide/chemistry platforms in key crops.
Erosion risks
- Corporate separation reduces integrated R&D/commercial alignment
- Regulatory and litigation risk in agrochemicals affects product economics
- Grower preference shifts toward alternative platforms
Leading indicators
- Adoption trends for integrated systems (e.g., Enlist)
- Cross-segment collaboration metrics pre-separation
- Regulatory/litigation developments affecting key products
Counterarguments
- Farmers can multi-home across chemistry platforms; loyalty may be limited
- Competitors can offer competing systems and bundling arrangements
Evidence
"Seed continues to benefit from its strength in advanced genetics, growth in out-licensing ..."
Management explicitly ties Seed performance to advanced genetics and out-licensing (an IP monetization signal).
"The increase in price is due primarily to increased out-licensing income ..."
Out-licensing income suggests valuable proprietary traits/germplasm used by other market participants.
"Corteva has invested $8.9 billion in cumulative research and development since 2019."
Sustained R&D spend supports a large, continuously improving genetics pipeline.
"Corteva has launched over 2,500 new Seed and Crop Protection products since 2019."
High launch cadence indicates an active pipeline and commercialization capability.
"The combined business model has historically delivered strong synergies ... [and] bundled solutions for farmers."
Reuters summarizes the value of integrated seed + crop protection offerings; relevant for 'system' adoption dynamics.
Showing 5 of 9 sources.
Risks & Indicators
Erosion risks
- Trait patent expirations and generic trait entry
- Regulatory restrictions on biotech traits or gene-editing
- Breakthrough competitor genetics/traits reduce differentiation
- R&D productivity slowdown (lower yield gains per dollar)
- Faster competitor product cycles (e.g., AI-enabled breeding)
- Farmer down-cycling to lower-priced seed alternatives
Leading indicators
- Out-licensing/royalty income trend
- Adoption rates of core trait platforms (e.g., Enlist system)
- Pipeline milestones and regulatory approvals for new traits
- R&D expense trend and pipeline launch cadence
- Relative performance in third-party yield trials
- Seed price/mix realization vs prior year
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.